Pharmaceuticals News and Research

RSS

Positive CHMP opinion recognizes efficacy of Biogen’s SPINRAZA for treatment of spinal muscular atrophy

Biogen today announced the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the granting of a marketing authorization for SPINRAZA to treat patients with spinal muscular atrophy (SMA).

21 Apr 2017

Researchers use gene-editing tool to restore visual function in mouse models of retinitis pigmentosa

Using the gene-editing tool CRISPR/Cas9, researchers at University of California San Diego School of Medicine and Shiley Eye Institute at UC San Diego Health, with colleagues in China, have reprogrammed mutated rod photoreceptors to become functioning cone photoreceptors, reversing cellular degeneration and restoring visual function in two mouse models of retinitis pigmentosa.

21 Apr 2017

Researchers reveal promising performance of retinal prosthesis implanted in rats

Researchers at Okayama University report in the Journal of Artificial Organs the promising performance of a retinal prosthesis material when implanted in rats. The material is capable of converting external light stimuli into electric potentials that are picked up by neurons.

21 Apr 2017

Light can be used to control cellular functions, optogenetics study shows

Light can be used as an accurate method to control gene expression, shows groundbreaking optogenetics study by University of Colorado, Duke University and University of Helsinki researchers.

21 Apr 2017

3D printing technology to support bone healing acquired by DePuy Synthes

DePuy Synthes Products, Inc., part of the Johnson & Johnson Family of Companies, has acquired 3D printing technology from Tissue Regeneration Systems, Inc. (TRS). The 3D printing methods developed by TRS will help enable DePuy Synthes to create patient-specific, bioresorbable implants with a unique mineral coating intended to support bone healing in patients with orthopaedic and craniomaxillofacial deformities and injuries. Financial terms of the transaction have not been disclosed.

20 Apr 2017

Fungi have immense potential for production of pharmaceutical compounds

Fungi are a potential goldmine for the production of pharmaceuticals. This is shown by researchers at Chalmers University of Technology, who have developed a method for finding new antibiotics from nature's own resources.

20 Apr 2017

Drug created from malaria protein offers hope for bladder cancer patients

A drug created from a malaria protein stopped tumor growth of chemotherapy-resistant bladder cancer, offering hope for cancer patients not responding to standard treatments.

20 Apr 2017

Scientists find new way to measure tau protein levels in the blood

Damaging tangles of the protein tau dot the brains of people with Alzheimer's and many other neurodegenerative diseases, including chronic traumatic encephalopathy, which plagues professional boxers and football players.

20 Apr 2017

Addressing unmet needs in prostate cancer

Prostate cancer is the second most diagnosed cancer globally with over a million men diagnosed worldwide. We are fortunate in that better diagnostic techniques and better awareness means that men are often being diagnosed earlier, which gives them a better chance of being cured.

19 Apr 2017

Pharmaceuticals containing cannabinoids may be effective against skin diseases, say researchers

Cannabinoids contain anti-inflammatory properties that could make them useful in the treatment of a wide-range of skin diseases, according to researchers at the University of Colorado Anschutz Medical Campus.

18 Apr 2017

TSRI scientists develop easy method for synthesizing compounds with potential to treat lung disorders

Chemists at The Scripps Research Institute have developed a broad and strikingly easy method for synthesizing a class of molecules that have demonstrated value as pharmaceuticals.

17 Apr 2017

Cell cultures in petri dishes open new doors to brain research

The most complex organ in humans is the brain. Due to its complexity and, of course, for ethical reasons, it is extremely difficult to do scientific experiments on it - ones that could help us to understand neurodegenerative diseases like Parkinson's, for example.

13 Apr 2017

Study finds depression and SUD to be strongest risk factors for prescription opioid overdose

Individuals suffering from a substance use disorder (SUD) or depression are among those at highest risk for a serious prescription opioid overdose, according to a study published in Pain Medicine.

13 Apr 2017

Lung experts develop new smartphone app for self-management of asthma

A new and unique smartphone app to help people with asthma manage their condition has been developed by lung experts at the Nottingham Respiratory Research Unit and the pharmaceutical company GlaxoSmithKline.

12 Apr 2017

New model can simplify process of identifying optimal blends for drug cocktails

Drug cocktails such as those for treating cancer, like the alcoholic versions offered at the local bar, are best when the proper ingredients are mixed in the right proportions.

10 Apr 2017

BMJ Innovations releases first collaborative definition of patient centricity co-created by AstraZeneca

AstraZeneca today announced that BMJ Innovations has published the first collaborative definition of patient centricity for the pharmaceutical industry.

10 Apr 2017

JAPhA articles highlight role of pharmacists in controlling opioid crisis

Pharmacists often face serious challenges when trying to balance the needs of patients with chronic pain and preventing prescription drug misuse, abuse, and overdose.

7 Apr 2017

New research effort aims to better understand impact and progression of COPD

Duke University's MURDOCK Study, the Duke Clinical Research Institute and Boehringer Ingelheim Pharmaceuticals Inc. announced today the launch of a new collaborative research effort to closely follow 850 people living with chronic obstructive pulmonary disease (COPD).

7 Apr 2017

BrainDx develops new measurement tool for precise diagnosis of ADHD and autism

Software company BrainDx (http://braindx.net/) announces a pioneering measurement tool to assist practitioners and researchers in differentiating between ADHD and autism spectrum disorder (ASD) in children.

7 Apr 2017

Galenica Group focuses on pharmaceuticals as it becomes Vifor Pharma Group

The Galenica Group announced today that it successfully completed the initial public offering (IPO) of Galenica Santé, its leading provider of health, beauty and well-being products and services on the Swiss Stock Exchange (SIX). Following the IPO, Galenica Group becomes Vifor Pharma Group and will be listed on the Swiss Stock Exchange under its new ticker, VIFN. The company has thus taken the final steps toward separating into two independent companies: Vifor Pharma Group and Galenica Santé.

From CSL Ltd 7 Apr 2017